Hysterectomy: What Needs to be Removed?

Mary Jane Minkin

Year in Review 2024 - Ovarian Cancer

Oncology 2024 Year in Review

E. Crane

Recent FDA Indications in Endometrial Cancers

Brian Slomovitz

ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Adv…

2024 ESMO Annual Meeting Insights Hub

B. Monk

IGCS 2024 Summary and Highlights: Key Trial Insights on Endometrial …

UCLA Health

D. Chase

Year in Review 2024 - Endometrial Cancer

Mansoor Raza Mirza

Endometrial Cancer: Risk Factors, Prognostic Challenges, and Staging…

Hope Cottrill

ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Adva…

2024 ESMO Annual Meeting Insights Hub

M. Raza Mirza

Gynecologic Oncology Updates: Expert Perspective on Key Trial Findin…

Yale Cancer Center

E. Ratner

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

SOCCER-P Trial: Secondary Cytoreductive Surgery in Relapsed Ovarian …

Hyun-Woong Cho

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

2024 ASCO® Annual Meeting Insights Hub

M. Raza Mirza

The Changing Field of Endometrial Cancer Treatment

GRACE

M. Raza Mirza

Endometrial Cancer: The Current Treatment Landscape

Hope Cottrill

Early Detection and Risk Prediction in Ovarian Cancer: The Role of m…

Ovarian Cancer Midwest Focus, University of Minnesota

K. Elias

OVATION 2 Trial: IMNN-001 Immunotherapy + Chemo for Advanced Ovarian…

Premal Thaker

ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagn…

2024 ESMO Annual Meeting Insights Hub

B. Monk

ESMO 2024 Insights: Pembro or Placebo in Combination With Adjuvant C…

2024 ESMO Annual Meeting Insights Hub

B. Slomovitz